Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18986934 | METHOD OF TREATING CANCER WITH A SELENIDE | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18895208 | METHOD OF TREATING CANCER IN A SUBJECT | September 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18771595 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | July 2024 | November 2024 | Allow | 4 | 0 | 0 | No | No |
| 18733183 | METHOD OF TREATING CANCER AND BONE CANCER PAIN | June 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18670277 | INJECTABLE BUPRENORPHINE FORMULATION | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18653685 | New Centrally-Active Ghrelin Agonist and Medical Uses Thereof | May 2024 | May 2025 | Allow | 12 | 2 | 0 | No | No |
| 18653318 | RESCUE TREATMENT OF POST OPERATIVE NAUSEA AND VOMITING | May 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18621682 | Isotopically Modified Composition and Therapeutic Uses Thereof | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18621067 | METHODS OF TREATING ACUTE DEPRESSION | March 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18620110 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | March 2024 | August 2024 | Allow | 5 | 0 | 0 | No | No |
| 18428087 | REGULATION OF eIF4E ACTIVITY FOR MIGRAINE THERAPY | January 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18417453 | PYRAZINO[1',2':1,5]PYRAZOLO[4,3-C][2,6]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | January 2024 | October 2024 | Allow | 9 | 1 | 0 | No | No |
| 18416023 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18402564 | 3-[4,4-BIS(4-NITROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18518709 | 2-(2-ETHOXYETHOXY)-6-(4-HYDROXYPHENYL)-4-(4-METHYLPHENYL)NICOTINONITRILE AS AN ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18517539 | Bioavailable Solid State (17-Beta)-Hydroxy-4-Androsten-3-One Esters | November 2023 | October 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18389078 | COMPOSITIONS AND METHODS FOR TREATING CANCER | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18506051 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18506036 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18506021 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | November 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18505898 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | November 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18506013 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | November 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18506029 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18502197 | SOTALOL COMPOSITIONS AND USES OF THE SAME | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18386161 | 6'-(4-BROMOPHENYL)-2'-METHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUND | November 2023 | March 2024 | Allow | 5 | 2 | 0 | No | No |
| 18493968 | METHODS OF TREATING ESTROGEN SENSITIVE DISEASES WITH CANNABIS EXTRACT | October 2023 | July 2024 | Allow | 9 | 1 | 1 | No | No |
| 18382952 | 2-(4-CHLOROPHENYL)-4,5-BIS(4-CHLOROPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18379839 | 6'-(2-CHLOROPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18480601 | METHODS OF TREATMENT USING BEMPEDOIC ACID | October 2023 | June 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18241598 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | September 2023 | June 2024 | Allow | 10 | 1 | 0 | No | No |
| 18235987 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | August 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18234648 | Treatment of Cancer with Naltrexone | August 2023 | March 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18364689 | TREATMENT OF SLEEP-WAKE DISORDERS | August 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18360292 | ANALYSIS METHOD OF 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT, TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS, INHIBITION OF PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS, AND METHOD OF PRODUCING MEDICAMENT CONTAINING 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT | July 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18224122 | NOVEL ANTITUMORAL USE OF CABAZITAXEL | July 2023 | June 2025 | Allow | 23 | 2 | 0 | No | No |
| 18351261 | Cardioversion Methods Using Budiodarone | July 2023 | July 2024 | Allow | 13 | 2 | 0 | No | No |
| 18350550 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES | July 2023 | December 2024 | Allow | 17 | 0 | 1 | No | No |
| 18212008 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | June 2023 | October 2023 | Allow | 4 | 1 | 0 | No | No |
| 18212029 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES | June 2023 | October 2023 | Allow | 4 | 1 | 0 | No | No |
| 18336658 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18203776 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | May 2023 | December 2024 | Allow | 19 | 1 | 0 | No | No |
| 18320339 | USE OF GABOXADOL FOR THE TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER | May 2023 | November 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18318804 | METHOD OF TREATING DEMENTIA | May 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18304511 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | April 2023 | August 2024 | Allow | 16 | 1 | 0 | No | No |
| 18302302 | ANTIMICROBIAL FORMULATIONS AND APPLICATIONS THEREOF | April 2023 | May 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18299664 | ANTI-INFECTIVE METHODS, COMPOSITIONS, AND DEVICES | April 2023 | June 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18130530 | Methotrexate Composition | April 2023 | May 2025 | Allow | 25 | 5 | 0 | No | No |
| 18130412 | NOVEL BROAD-SPECTRUM ANTITRYPANOSOMAL COMPOUNDS | April 2023 | August 2023 | Allow | 5 | 1 | 0 | No | No |
| 18185180 | Fluorinated Phenylamino Compounds and Pharmaceutical Compositions | March 2023 | May 2023 | Allow | 2 | 0 | 0 | No | No |
| 18119673 | METHODS FOR TREATMENT OF INTERSTITIAL CYSTITIS | March 2023 | October 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18110238 | COMBINATION DRUG PRODUCTS FOR TREATING PATIENTS SUFFERING FROM ONE OR MORE MEDICAL CONDITIONS CAUSED BY CORONAVIRUS INFECTION, INCLUDING BY SARS-CoV-2, ITS ALPHA, BETA, DELTA, OR OMICRON VARIANTS AND SUB VARIANTS | February 2023 | April 2024 | Allow | 14 | 2 | 0 | Yes | Yes |
| 18109561 | LIQUID NALOXONE SPRAY | February 2023 | May 2025 | Allow | 27 | 3 | 0 | No | No |
| 18108164 | METHODS AND COMPOSITIONS RELATING TO CLBP INHIBITION | February 2023 | July 2024 | Allow | 17 | 2 | 0 | No | No |
| 18167059 | GEL OPHTHALMIC FORMULATIONS OF PILOCARPINE AND BRIMONIDINE COMPOUNDS AND RELATED METHODS | February 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 18167057 | LOW PH PILOCARPINE AND BRIMONIDINE COMPOUND FORMULATIONS AND RELATED METHODS | February 2023 | December 2023 | Allow | 11 | 3 | 0 | No | No |
| 18102437 | Compositions and Methods for Treatment of Edema | January 2023 | July 2024 | Allow | 18 | 1 | 0 | No | No |
| 18095612 | USE OF AMISULPRIDE AS AN ANTI-EMETIC | January 2023 | September 2024 | Allow | 20 | 2 | 0 | No | No |
| 18010816 | USE OF CO-ENZYME ANTAGONISTS TO SLOW METABOLISM | December 2022 | August 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 17981140 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | November 2022 | February 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17976220 | NEW MEDICAL TREATMENT | October 2022 | May 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18048674 | FORMULATIONS OF VANCOMYCIN | October 2022 | October 2024 | Allow | 24 | 1 | 0 | No | No |
| 17966245 | DEUTERATED FORMS OF TESTOSTERONE AND METHODS OF USE | October 2022 | April 2024 | Allow | 18 | 0 | 0 | No | No |
| 17965529 | Method of Treating Cancer and Bone Cancer Pain | October 2022 | July 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17995621 | ORGANIC ACID ADDITION SALTS OF S-PINDOLOL | October 2022 | July 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17953530 | Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension | September 2022 | June 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17948542 | COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS | September 2022 | March 2025 | Allow | 29 | 0 | 1 | No | No |
| 17941648 | IBOGAINE COMBINATION TREATMENT | September 2022 | June 2024 | Abandon | 21 | 2 | 0 | No | No |
| 17888060 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | August 2022 | March 2023 | Allow | 7 | 2 | 0 | No | No |
| 17798391 | COMPOSITIONS AND METHODS FOR TREATING MALARIA | August 2022 | April 2025 | Allow | 32 | 0 | 0 | No | No |
| 17882946 | METHODS FOR MODIFYING ENDOPLASMIC RETICULUM PROCESSING OF PROTEIN | August 2022 | January 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17817619 | KIF5B-RET FUSION MOLECULES AND USES THEREOF | August 2022 | October 2024 | Allow | 27 | 1 | 0 | No | No |
| 17859743 | TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS | July 2022 | April 2025 | Allow | 33 | 0 | 0 | No | No |
| 17809353 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | June 2022 | November 2023 | Allow | 17 | 2 | 0 | No | No |
| 17809327 | METHOD FOR INHIBITING DENGUE VIRUS INFECTION | June 2022 | December 2023 | Allow | 18 | 1 | 0 | No | No |
| 17809345 | METHOD FOR INHIBITING DENGUE VIRUS INFECTION | June 2022 | August 2023 | Allow | 14 | 1 | 0 | No | No |
| 17809339 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | June 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17778588 | MASITINIB FOR THE TREATMENT OF SICKLE CELL DISEASE | May 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17746032 | RESCUE TREATMENT OF POST OPERATIVE NAUSEA AND VOMITING | May 2022 | January 2024 | Allow | 20 | 2 | 0 | No | No |
| 17661971 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | May 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17730853 | ANALYSIS METHOD OF 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT, TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS, INHIBITION OF PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS, AND METHOD OF PRODUCING MEDICAMENT CONTAINING 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT | April 2022 | April 2023 | Allow | 11 | 2 | 1 | No | No |
| 17771949 | METHODS AND COMPOSITIONS RELATING TO CLBP INHIBITION | April 2022 | December 2022 | Allow | 7 | 1 | 0 | No | No |
| 17719718 | Docetaxel-Aconitic Anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity | April 2022 | May 2025 | Allow | 37 | 1 | 0 | No | No |
| 17713576 | METHODS FOR THE TREATMENT OF MYCOBACTERIUM INFECTIONS | April 2022 | February 2024 | Allow | 22 | 1 | 0 | No | No |
| 17708732 | KITS AND METHODS FOR INDUCTION OF CARDIOVERSION IN SUBJECTS WITH ATRIAL ARRHYTHMIAS | March 2022 | January 2023 | Allow | 9 | 2 | 1 | No | No |
| 17698814 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER | March 2022 | January 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17696075 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | March 2022 | November 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17694827 | Bioavailable Solid State (17-Beta)-Hydroxy-4-Androsten-3-One Esters | March 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17687682 | COMPOSITION FOR AMELIORATING PSORIASIS COMPRISING CIMICIFUGOLIDE A AS ACTIVE INGREDIENT | March 2022 | February 2024 | Allow | 23 | 2 | 0 | No | No |
| 17684154 | HEMP EXTRACT FOR TREATMENT OF PAIN IN ANIMALS | March 2022 | October 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17670698 | BUFFERED SILVER COMPLEX BIOCIDE | February 2022 | December 2024 | Abandon | 34 | 2 | 0 | No | Yes |
| 17670604 | METHOD OF TREATING C3 GLOMERULOPATHY | February 2022 | August 2023 | Allow | 18 | 1 | 0 | No | No |
| 17586160 | EUTECTIC FORM A OF ELAGOLIX AND PYRIMETHAMINE, PREPARATION METHOD THEREFOR AND USE THEREOF | January 2022 | January 2025 | Allow | 35 | 0 | 0 | No | No |
| 17629218 | INHIBITOR COMPOUNDS | January 2022 | June 2025 | Allow | 41 | 1 | 0 | No | No |
| 17579013 | PHARMACEUTICAL COMPOSITION EXHIBITING ANTI-TUMOR ACTIVITY, METHOD FOR TREATING PATIENT SUFFERING FROM CANCER AND METHOD FOR INHIBITING TUMOR GROWTH | January 2022 | July 2024 | Allow | 30 | 1 | 0 | No | No |
| 17621576 | SMALL MOLECULE INHIBITORS FOR TREATING CANCER IN A SUBJECT HAVING TUMORS WITH HIGH INTERSTITIAL PRESSURE | December 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17556859 | DEUTERATED FORMS OF TESTOSTERONE AND METHODS OF USE | December 2021 | July 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17552609 | APPLICATION OF 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES IN ANTIVIRAL THERAPY | December 2021 | May 2023 | Abandon | 17 | 3 | 0 | No | No |
| 17550538 | TREATMENT OF RESTENOSIS USING TEMSIROLIMUS | December 2021 | May 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17549104 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | December 2021 | June 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17547676 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | December 2021 | December 2022 | Abandon | 12 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ANDERSON, JAMES D.
With a 9.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ANDERSON, JAMES D works in Art Unit 1629 and has examined 1,145 patent applications in our dataset. With an allowance rate of 58.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.
Examiner ANDERSON, JAMES D's allowance rate of 58.8% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ANDERSON, JAMES D receive 1.92 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ANDERSON, JAMES D is 26 months. This places the examiner in the 59% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +17.8% benefit to allowance rate for applications examined by ANDERSON, JAMES D. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 24.4% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 53.7% of cases where such amendments are filed. This entry rate is in the 75% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 67.6% of appeals filed. This is in the 48% percentile among all examiners. Of these withdrawals, 76.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 50.9% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.8% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.